Results for this period
Interim period (second quarter)1 April 2026 to 30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ thousand).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Research and development expenses increased 49.7% year on year due to higher joint research costs with Stanford University and the cessation of joint research and development funding received from the joint research and development partner following approval to manufacture and market ReHeart.
No matters to report
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 September 2026 |
| Net Sales | ¥52 million (YoY -72.8%) |
| Operating profit | ¥-685 million |
| Ordinary income | ¥-526 million |
| Profit attributable to owners of the parent | ¥-526 million |
| Net income per share | -¥63.61 |
| Equity ratio | End of the current fiscal period 84.2 / End of previous period 91.6 |
| Total assets | ¥8,549 million |
| Net assets | ¥7,261 million |
| Cash flows from operating activities | ¥-783,933 thousand |
| Cash flows from investing activities | ¥-334,960 thousand |
| Cash flows from financing activities | ¥3,993,358 thousand |
| Cash and cash equivalents at end of period | ¥6,774,460 thousand |
| Full-year earnings forecast | Net Sales ¥540 million (YoY +154.3%) / Operating profit ¥-1,030 million / Ordinary income ¥-580 million / Profit attributable to owners of the parent ¥-570 million |
| Annual Dividend Forecast | ¥0 → ¥0（0.0%） |
| Depreciation and amortization | ¥69,709 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on reversal of stock acquisition rights ¥2,237 thousand / Extraordinary loss Not disclosed |
| Disclosure regarding the going concern assumption | No matters to report |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New: 0 companies; excluded: 0 companies; no material changes to the scope of consolidation |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | None (an earnings presentation video is scheduled to be distributed on the company's website) |
| Issued Shares at Period-End | 8,896,416 shares |
| Treasury Shares at Period-End | 15,896 treasury shares |
| Factors Behind Changes in Business Performance | Research and development expenses increased 49.7% year on year due to higher joint research costs with Stanford University and the cessation of joint research and development funding received from the joint research and development partner following approval to manufacture and market ReHeart. |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Research and development expenses increased due to higher joint research costs with Stanford University, as well as the cessation of joint research and development funding received from the joint research and development partner following approval to manufacture and market ReHeart.